Know Cancer

forgot password

Beacon® Transponder Implantation and Localization in the Prostate

18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

Beacon® Transponder Implantation and Localization in the Prostate

The goal for prostate radiation therapy is to give a high dose of radiation to the prostate
and a minimal dose to the healthy tissue around the prostate. It is well known that the
prostate moves slightly within the pelvis and that its position varies a few millimeters
from day to day. There are several methods used to position the body and the prostate
accurately at the beginning of each radiation therapy session.

One of the standard methods is to permanently implant small markers (gold spheres or
cylinders) in the prostate and use x-rays in the radiation therapy treatment room to
determine whether the markers are in the correct position. If the markers are in the
correct position, then the assumption is that the prostate also is in the correct position.
If the markers are not in the correct position on the x-ray, then the table that the patient
lies on can be shifted so that the markers are in the right place.

In this study the Beacon® transponder will be used in place of the standard gold marker.
During the radiation therapy visits, the patient position in the treatment room will be
corrected using the Beacon transponder with an investigational system, called the Calypso®
4D Localization System. The Calypso system consists of a flat panel, placed over the pelvis
and connected to a computer, which monitors the position of the Beacon transponders within
the prostate. During five radiation therapy appointments and one extra visit, the position
of the markers in the prostate will be confirmed with x-rays.

The Beacon transponder is a small glass cylinder that contains a tiny electrical circuit.
The glass vial is completely sealed and separates the internal components (i.e., the
electrical circuit) from the rest of the body. The glass vial is approximately one-third of
one inch long and one-tenth of one inch in diameter. Three Beacon transponders will be
implanted in the prostate. They will be permanently implanted.

Inclusion Criteria:

- 18 years of age or older

- Histologically confirmed diagnosis of prostate cancer

- Intact prostate (minor transurethral resection of the prostate [TURP] defects are
allowed at the discretion of the investigator)

- Ability to comply with study visit schedule

Exclusion Criteria:

- Prior treatment for prostate cancer.

- Prostate cancer stage IV (metastatic disease).

- Patients who are not eligible for prostate biopsy.

- Past history of abdominoperineal (A-P) resection.

- Planned course of treatment using brachytherapy (permanent brachytherapy seeds or
high dose rate [HDR] brachytherapy).

- Allergy to local anesthetics.

- Patients with any permanently implanted medical devices that have an energy source,
such as pacemakers, defibrillators, neurostimulators, and drug infusion pumps; this
also includes prosthetic implants in the abdomen or pelvis, such as an artificial
hip; or vascular implants such as arterial stents or stent-grafts for aortic
aneurysms. This does not include surgical clips, staples or coronary stents.

- History of chronic prostatitis.

- Patients with a history of recent acute and/or chronic bleeding disorders.

- Patients on therapeutic anti-coagulants or anti-platelet therapy, not including

- Patients for which the maximum anterior-posterior separation through the torso minus
the height of the center of the prostate is greater than 23 cm. (Measurements will
be made visually with a ruler.)

- Baseline evaluation shows an INR or PTT outside of the normal range for the
institution; platelet count < 75,000 mm3; or creatinine > 2.0 mg/dl.

- Any other medical condition or laboratory value that would, at the discretion of the
investigator, preclude the patient from participation in a clinical trial

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Radiographic verification of at least five of approximately 40 radiation treatment days

Outcome Time Frame:

8 weeks

Safety Issue:


Principal Investigator

Lisa Levine, Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

Varian Medical


United States: Food and Drug Administration

Study ID:

Prostate Stage 3



Start Date:

July 2005

Completion Date:

September 2008

Related Keywords:

  • Prostate Cancer
  • Prostate
  • Cancer
  • Radiotherapy
  • Neoplasm
  • Localization
  • Tracking
  • Cancer of Prostate
  • Neoplasms, Prostate
  • Prostatic Neoplasms



Sharp Memorial Hospital San Diego, California  92123
The Cleveland Clinic Cleveland, Ohio  44195
M.D. Anderson Cancer Center Orlando Orlando, Florida  32806
The Nebraska Medical Center Omaha, Nebraska  68198
Scottsdale Healthcare - Osborn Scottsdale, Arizona  85260